We investigated tumor microenvironment (TME) immunophenotype, tissue genomic features, ctDNA, and exosomes within the TWIN study, a prospective observational study of first-line dabrafenib and trametinib in BRAFV600 mutated MM patients treated in Italian Melanoma Intergroup centers. Between November 2017 to May 2019, 201 patients were enrolled; 160 had at least one valid baseline sample and constituted the biomarker analysis population. Among them, mean age was 61.9, 62.5% were male, ECOG performance status was 0 in 73.8%, TNM stage was predominantly M1c (35.6%) or M1d (25.6%), LDH was >ULN in 36.3%, and 48.1% had ≥3 metastatic sites.
Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib / Mandalà, M., Tucci, M., Cristina Sini, M., Baglivo, S., Simi, S., Costabile, S., Gambale, E., Quitadamo, C., Leone, P., Racanelli, V., Grazia Doro, M., Frogheri, L., Persico, I., Viapiana, N., Massi, D., Palmieri, G.. - In: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. - ISSN 0926-9959. - (2026).
Tissue and circulating biomarkers in advanced melanoma patients receiving dabrafenib and trametinib
Giuseppe Palmieri
2026-01-01
Abstract
We investigated tumor microenvironment (TME) immunophenotype, tissue genomic features, ctDNA, and exosomes within the TWIN study, a prospective observational study of first-line dabrafenib and trametinib in BRAFV600 mutated MM patients treated in Italian Melanoma Intergroup centers. Between November 2017 to May 2019, 201 patients were enrolled; 160 had at least one valid baseline sample and constituted the biomarker analysis population. Among them, mean age was 61.9, 62.5% were male, ECOG performance status was 0 in 73.8%, TNM stage was predominantly M1c (35.6%) or M1d (25.6%), LDH was >ULN in 36.3%, and 48.1% had ≥3 metastatic sites.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
